On April 5, 2019, Phigenix met with the Center for Cancer Research and Therapeutic Development (CCRTD) in Atlanta, GA to discuss a potential collaboration for the development of a prostate cancer therapeutic and a companion diagnostic. The meeting was hosted by CCRTD Director, Dr. Shafiq Kahn and the Chief Commercial and Technology Transfer Officer, Mrs. Lativia Ray-Alston . Representing Phigenix was President and CEO Dr. Carlton D. Donald, along with Dr. James P. Brown, Head of Research and Development, and Mr. Phillip Howard, Head of Business Development. Both parties were excited about the possibility forging a mutually beneficial business relationship and have planned further discussions.